KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance

Stock Information for KORU Medical Systems Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About KORU Medical Systems Inc.

KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
KORU Medical Systems Announces CEO Transition
KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic
KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.